What did @drkendalstewart actually say?
Dr. Kendal Stewart offers a two-part claim: first, a brief and mostly reasonable explanation of what peptides are, and second, a specific historical origin story. He says that in 2008, the Russian Federation of Sciences was tasked with helping athletes cheat undetected. Their solution, he argues, was to fragment existing hormones into smaller peptide pieces that evaded drug testing while producing targeted effects. He finishes with a sweeping conclusion: because peptides manipulate the body's "natural functions," their side effect profile "compared to a medication is just essentially non-existent."
The basic biochemistry is fine. The origin story is not well-supported. And that final safety claim is the kind of thing that should make any informed viewer pump the brakes.
Does the science back this up?
Partially, but the 2008 Russian Federation story does not hold up as the origin of peptide research. Peptide science predates it by decades, and the "chopped up hormone" framing is a significant oversimplification of how synthetic peptides are actually developed.
The history of therapeutic peptides starts well before 2008. Insulin, a peptide hormone, was first used therapeutically in 1922. Research into growth hormone fragments like AOD-9604 dates to the 1990s at Monash University. GHRP-6, a synthetic growth hormone secretagogue, was described by Bowers and colleagues in the 1980s (Bowers et al., 1984, Endocrinology). BPC-157, perhaps the most discussed peptide in this category, was first studied by Sikiric and colleagues in Croatia in the early 1990s, well before 2008 (Sikiric et al., 1993, Journal of Physiology-Paris).
The Russian doping angle has some basis in reality. WADA investigations, including the McLaren Report of 2016, documented state-sponsored doping programs. Peptides like GHRP-2 and GHRP-6 have appeared on doping violation lists. But framing this as the origin of the entire peptide field misrepresents decades of legitimate biochemical and pharmaceutical research.
What did they get wrong (or right)?
Credit where it's due: the basic definition of peptides as short amino acid chains is accurate. The point that peptides can target specific physiological effects is also reasonable and supported by the pharmacological literature on receptor-selective peptides.
Where the video goes wrong is the origin narrative and the safety claim. Attributing peptide therapy to a 2008 Russian doping program is not supported by the published scientific record. It is a compelling story, but compelling is not the same as accurate.
The bigger problem is the claim that side effects are "essentially non-existent." This is not what the evidence shows. Known adverse effects across various peptides include:
- Injection site reactions, which are among the most commonly reported issues in clinical use
- Water retention and joint discomfort with growth hormone secretagogues like CJC-1295 and ipamorelin (Sigalos and Pastuszak, 2018, Sexual Medicine Reviews)
- Potential effects on insulin sensitivity with MK-677 (Nass et al., 2008, Journal of Clinical Endocrinology and Metabolism)
- Largely unknown long-term safety profiles for most research peptides, because controlled human trials are still limited
Saying the side effect profile is "essentially non-existent" when most of these compounds lack Phase III human trial data is a stretch that could genuinely mislead patients.
What should you actually know?
Peptides are a legitimate and rapidly evolving area of both pharmaceutical research and clinical practice. Some, like semaglutide and tirzepatide, have completed rigorous clinical trials and received FDA approval. Others, like BPC-157 and TB-500, remain research compounds with no approved human indication in the United States, despite significant preclinical data and widespread off-label use.
The regulatory and safety landscape here matters. Compounded peptides obtained through telehealth platforms are not FDA-approved drugs, and their purity, potency, and long-term safety are not guaranteed by the same standards applied to approved medications. That does not mean they are ineffective or inherently dangerous, but it does mean the "essentially no side effects" framing is irresponsible without that context.
A more honest frame is this: some peptides show real promise in early research, a smaller number have strong clinical evidence, and almost all of them require a provider who actually understands the pharmacology, your individual health status, and the limits of what is currently known. The 2008 Russian doping story makes for a fun origin myth. The actual history of peptide science is older, more global, and considerably more rigorous than that story implies.